[Anti-TNF alpha in dermatology]

Area of Science:

• Immunology
• Pharmacology
• Dermatology

Context:

• Tumor necrosis factor (TNF) alpha plays a key role in inflammatory diseases.
• Biotechnology has yielded effective anti-TNF alpha drugs for rheumatoid arthritis and Crohn's disease.
• Etanercept and infliximab are leading anti-TNF alpha therapies.

Purpose:

• To review the role of anti-TNF alpha therapies in inflammatory diseases.
• To explore the potential of anti-TNF alpha agents in dermatological conditions.
• To highlight the need for rigorous assessment and pharmacovigilance of these treatments.

Summary:

• Anti-TNF alpha drugs, including etanercept and infliximab, have proven effective for rheumatoid arthritis and Crohn's disease.
• Emerging anti-TNF alpha therapies show promise for various skin inflammatory diseases, with initial positive results in psoriasis.
• Further research and post-marketing surveillance are crucial to evaluate the long-term efficacy and safety of these treatments in dermatology.

Impact:

• Anti-TNF alpha therapies represent a significant advancement in managing inflammatory and autoimmune diseases.
• The expansion of anti-TNF alpha treatments into dermatology offers new therapeutic options for patients with severe skin conditions.
• Dermatologists play a vital role in assessing the clinical utility and monitoring the safety of these novel biologic agents.